Volume 19, Number 6—June 2013
Research
Characteristics of Group A Streptococcus Strains Circulating during Scarlet Fever Epidemic, Beijing, China, 2011
Peng Yang1, Xiaomin Peng1, Daitao Zhang, Shuangsheng Wu, Yimeng Liu, Shujuan Cui, Guilan Lu, Wei Duan, Weixian Shi, Shuang Liu, Jing Li, and Quanyi Wang
Table 1
SAgs and emm types of group A Streptococcus circulating during a scarlet fever epidemic, Beijing, China, 2011*
| emm type or SAg | No. (%) patients, by age |
p value | No. (%) patients, by sex |
p value | No. (%) patients, by clinical diagnosis |
p value | Total, n = 647 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| <5 y, n = 246 | >5 y, n = 401 | Male, n = 402 | Female, n = 245 | Scarlet fever, n = 430 | Pharyngitis, n = 217 | |||||
| emm type | ||||||||||
| 12 | 203 (82.5) | 291 (72.6) | 0.004 | 303 (75.4) | 191 (78.0) | 0.453 | 331 (77.0) | 163 (75.1) | 0.599 | 494 (76.4) |
| 1 | 34 (13.8) | 77 (19.2) | 0.078 | 73 (18.2) | 38 (15.5) | 0.386 | 83 (19.3) | 28 (12.9) | 0.042 | 111 (17.1) |
| Other† |
9 (3.7) |
33 (8.2) |
0.022 |
26 (6.5) |
16 (6.5) |
0.975 |
16 (3.7) |
26 (12.0) |
<0.001 |
42 (6.5) |
| SAg | ||||||||||
| SpeA | 47 (19.1) | 96 (23.9) | 0.150 | 91 (22.6) | 52 (21.2) | 0.675 | 99 (23.0) | 44 (20.3) | 0.427 | 143 (22.1) |
| SpeB | 246 (100.0) | 401 (100.0) | NA | 402 (100.0) | 245 (100.0) | NA | 430 (100.0) | 217 (100.0) | NA | 647 (100.0) |
| SpeC‡ | 243 (98.8) | 400 (99.8) | 0.156 | 398 (99.0) | 245 (100.0) | 0.303 | 427 (99.3) | 216 (99.5) | 1.000 | 643 (99.4) |
| SpeF‡ | 245 (99.6) | 400 (99.8) | 1.000 | 401 (99.8) | 244 (99.6) | 1.000 | 429 (99.8) | 216 (99.5) | 1.000 | 645 (99.7) |
| SpeG‡ | 246 (100.0) | 399 (99.5) | 0.528 | 400 (99.5) | 245 (100.0) | 0.529 | 428 (99.5) | 217 (100.0) | 0.554 | 645 (99.7) |
| SpeH | 192 (78.0) | 301 (75.1) | 0.387 | 299 (74.4) | 194 (79.2) | 0.164 | 326 (75.8) | 167 (77.0) | 0.747 | 493 (76.2) |
| SpeI | 190 (77.2) | 302 (75.3) | 0.578 | 301 (74.9) | 191 (78.0) | 0.373 | 327 (76.0) | 165 (76.0) | 1.000 | 492 (76.0) |
| SpeJ | 47 (19.1) | 92 (22.9) | 0.249 | 87 (21.6) | 52 (21.2) | 0.900 | 99 (23.0) | 40 (18.4) | 0.180 | 139 (21.5) |
| SpeK ‡ | 1 (0.4) | 3 (0.7) | 1.000 | 1 (0.2) | 3 (1.2) | 0.155 | 0 | 4 (1.8) | 0.012 | 4 (0.6) |
| SpeL ‡ | 2 (0.8) | 5 (1.2) | 0.715 | 4 (1.0) | 3 (1.2) | 1.000 | 2 (0.5) | 5 (2.3) | 0.046 | 7 (1.1) |
| SpeM | 5 (2.0) | 9 (2.2) | 0.857 | 8 (2.0) | 6 (2.4) | 0.697 | 9 (2.1) | 5 (2.3) | 0.862 | 14 (2.2) |
| SmeZ‡ | 245 (99.6) | 400 (99.8) | 1.000 | 401 (99.8) | 244 (99.6) | 1.000 | 428 (99.5) | 217 (100.0) | 0.554 | 645 (99.7) |
| Ssa | 241 (98.0) | 391 (97.5) | 0.705 | 394 (98.0) | 238 (97.1) | 0.477 | 427 (99.3) | 205 (94.5) | <0.001 | 632 (97.7) |
*Boldface indicates statistical significance. SAg, superantigen.
†Other emm types included types 4, 11, 22, 75, and 89.
‡Fisher exact test was used.
1These authors contributed equally to this article.
Page created: May 03, 2013
Page updated: May 03, 2013
Page reviewed: May 03, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.